Literature DB >> 25092090

Neuroblastoma: outcome over a 14 year period from a tertiary care referral centre in India.

Sandeep Agarwala1, Ankur Mandelia2, Sameer Bakhshi3, M Srinivas2, Minu Bajpai2, Arun K Gupta4, Devendra K Gupta2, Veereshwar Bhatnagar2.   

Abstract

PURPOSE: To evaluate the outcome of children with neuroblastoma (NB) from a tertiary care referral centre in India.
METHOD: All children with NB registered from October 1996 through July 2009 were included in the study. INSS was used for staging. All children included in the study received chemotherapy and radiation therapy appropriate for stage. Tumor resection was done when feasible. The final outcome was overall survival and it was categorized as Complete Response (CR), Partial Response (PR); No Response (NR) and Progressive Disease (PD). Analysis of three-year overall survival was done using Kaplan Meier method and Log Rank test of significance. Multivariate analysis for significance of age, site and stage was performed.
RESULTS: 144 children in the age range of 1-132months (median 36) were enrolled. Only 38 (26.4%) children were below 12months. 112 (77.8%) of the tumors were abdominal and 32 (22.2%) were extra-abdominal. Stage distribution was 1+2 in 6 (4.2%); 3 in 58 (40.3%); 4 in 68 (47.2%); 4s in 12 (8.3%). 83 (57.6%) underwent gross complete resection. At the time of last follow-up, 100 (69.4%) were alive [60 CR (41.7%); 33 PR; 7 PD/NR] and 44 (30.6%) were dead [1CR; 11PR; 32 PD/NR]. The three-year OS was 60.7% [95 CI 50.4-69.5]. The OS was 69.7% for those<12months of age [95 CI 51.8-82.0] and CR was achieved in 57.9%, while for those >12months the OS was 55.3% [95 CI 42.2-66.6] and CR was achieved in 35.8% (p=0.73). All 6 (100%) patients with Stage 1 and Stage 2 disease were alive and disease free. The OS was 71.5% for Stage 3[95 CI 55.3-82.7] and CR was achieved in 56.9%, while for Stage 4 the OS was 35.7%[95 CI 19.3-52.4] and CR was achieved in 17.6% (p=0.001). The OS was 83.3% for 4s [95 CI 48.2-95.6] and CR was achieved in 75%.
CONCLUSION: All the six children with Stage 1 &amp; 2 achieved CR and were alive, while 57% of Stage 3 could achieve CR and had an OS of 71.5%. The OS (35.7%) and CR (17.6%) for Stage 4 were significantly less (p=0.001).
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuroblastoma; Outcome; Survival; Treatment

Mesh:

Year:  2014        PMID: 25092090     DOI: 10.1016/j.jpedsurg.2014.03.017

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  6 in total

Review 1.  Neuroblastoma in a Developing Country: Miles to Go.

Authors:  Jagdish Prasad Meena; Aditya Kumar Gupta
Journal:  Indian J Pediatr       Date:  2019-03-26       Impact factor: 1.967

2.  Editorial: Indian Guidelines for Treatment of Pediatric Malignancies.

Authors:  Akash Tiwari; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2017-03-16       Impact factor: 1.967

Review 3.  Management of Neuroblastoma: ICMR Consensus Document.

Authors:  Deepak Bansal; Sidharth Totadri; Girish Chinnaswamy; Sandeep Agarwala; Tushar Vora; Brijesh Arora; Maya Prasad; Gauri Kapoor; Venkatraman Radhakrishnan; Siddharth Laskar; Tanvir Kaur; G K Rath; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2017-04-03       Impact factor: 1.967

4.  Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India.

Authors:  Venkatraman Radhakrishnan; Anand Raja; Manikandan Dhanushkodi; T S Ganesan; G Selvaluxmy; T G Sagar
Journal:  Indian J Pediatr       Date:  2019-02-18       Impact factor: 1.967

5.  Pediatric Neuroblastoma - Impact of Nutritional Status on Complications and Outcomes.

Authors:  Ruchira Nandan; Shilpa Sharma; Minu Bajpai; Vishesh Jain; Prabudh Goel; Devendra Kumar Yadav
Journal:  J Indian Assoc Pediatr Surg       Date:  2022-03-01

6.  Access to care for childhood cancers in India: perspectives of health care providers and the implications for universal health coverage.

Authors:  Neha Faruqui; Sarah Bernays; Alexandra Martiniuk; Seye Abimbola; Ramandeep Arora; Jennifer Lowe; Avram Denburg; Rohina Joshi
Journal:  BMC Public Health       Date:  2020-11-03       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.